| 商品名称 | Nobivac Piro |
|---|
| 适用类别 | Veterinary |
|---|
| 治疗领域 | |
|---|
| 通用名/非专利名称 | vaccine against babesiosis in dogs |
|---|
| 活性成分 | babesia canis, inactivated;babesia rossi, inactivated |
|---|
| 产品号 | EMEA/V/C/000084 |
|---|
| 患者安全信息 | No |
|---|
| 许可状态 | Withdrawn |
|---|
| ATC编码 | QI07AO |
|---|
| 是否额外监管 | No |
|---|
| 是否仿制药或hybrid药物 | No |
|---|
| 是否生物类似药 | No |
|---|
| 是否附条件批准 | No |
|---|
| 是否特殊情形 | No |
|---|
| 是否加速审评 | No |
|---|
| 是否罕用药 | No |
|---|
| 上市许可日期 | 2004/09/02 |
|---|
| 上市许可开发者/申请人/持有人 | Intervet International BV |
|---|
| 人用药物治疗学分组 | |
|---|
| 兽用药物治疗学分组 | Immunologicals for canidae |
|---|
| 欧盟委员会决定日期 | 2013/05/22 |
|---|
| 修订号 | 4 |
|---|
| 治疗适应症 | For active immunisation of dogs of six months of age or older against Babesia canis to reduce the severity of clinical signs associated with acute babesiosis (B. canis) and anaemia as measured by packed cell volume. Onset of immunity: Three weeks after the basic vaccination course. Duration of immunity: Six months after the last (re-)vaccination. |
|---|
| 适用物种 | Dogs |
|---|
| 兽用药物ATC编码 | QI07AO |
|---|
| 首次发布日期 | 2013/05/22 |
|---|
| 最后更新日期 | 2013/05/30 |
|---|
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/nobivac-piro-epar-product-information_en.pdf |
|---|
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/veterinary/EPAR/nobivac-piro |
|---|